Compounding pharmacies in Connecticut
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
The Connecticut Commission of Pharmacy (Department of Consumer Protection, Drug Control Division) regulates compounding pharmacies in Connecticut. Compounded GLP-1 limited. How to check a pharmacy's license, plus listings with their verification status.
Connecticut at a glance
- Pharmacy regulator
- Connecticut Commission of Pharmacy (Department of Consumer Protection, Drug Control Division)
- 503A framework
- Follows the federal 503A framework
- Telehealth prescribing
- Regulatory: Telehealth allowed
- Asynchronous prescribing
- Regulatory: Async allowed
- Compounded GLP-1 access
- Regulatory: Compounded GLP-1 limited
Compounding pharmacies serving Connecticut
No verified compounding pharmacies serving Connecticut are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.
Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.
Run a pharmacy, clinic, or telehealth service? Apply for a listing.
Who regulates compounding pharmacies in Connecticut
Connecticut regulates pharmacies through the Department of Consumer Protection and the Commission of Pharmacy under chapter 400j of the General Statutes. Connecticut has no separate state bulks list, so peptide eligibility follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list). Two Connecticut rules matter for injectable peptides. First, a pharmacy outside Connecticut must hold a nonresident pharmacy registration under section 20-627 and disclose whether it dispenses sterile pharmaceuticals into the state. Second, section 20-633b defines a sterile compounding pharmacy to include registered nonresident pharmacies and requires a nonresident applicant that intends to compound sterile products for Connecticut patients to file an addendum, provide proof of a passed home-state inspection, and wait for written approval from the Department and the Commission before shipping. Connecticut's sterile compounding regulations (Regulations of Connecticut State Agencies sections 20-576-64 to 20-576-68, adopted 2011) apply to pharmacies licensed under section 20-594 and require compliance with the current USP chapter 797, a policy and procedure manual that complies with chapter 797, a two-week limit on compounded products supplied to practitioners for office use, and at least 35 open hours a week unless waived. Those regulations do not set separate compounding standards for nonresident pharmacies; a nonresident sterile compounder is governed by the section 20-633b addendum, inspection, and approval process described above. [1] [3] [4] [5] [6] [8]
Compounded GLP-1 access in Connecticut
Because compounded GLP-1 injections are sterile preparations, an out-of-state pharmacy shipping them to Connecticut must have an approved sterile compounding addendum under section 20-633b in addition to its nonresident registration. [4] [5] [11]
Research use only sellers in Connecticut
Only Connecticut-licensed pharmacies and registered nonresident pharmacies may dispense prescription drugs to Connecticut patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law, are not dispensed by a pharmacist, and fall outside Connecticut's sterile compounding approval system. Connecticut law also bars the sale directly: under the Connecticut Food, Drug and Cosmetic Act, section 21a-110 provides that no person shall sell, deliver, offer for sale, hold for sale, or give away any new drug unless an application for it has been approved under section 355 of the federal act or, for a drug not subject to the federal act, a state application has been filed with the Commissioner of Consumer Protection. The Connecticut Attorney General has used the Connecticut Unfair Trade Practices Act (Conn. Gen. Stat. 42-110a and following) against sellers of research-grade GLP-1s, including a 2025 settlement with an online distributor and a May 2026 settlement under which an international online trade platform agreed to stop GLP-1 sales to US consumers and remove such listings. The same May 2026 announcement included a settlement with a medical spa that stopped advertising and prescribing compounded semaglutide and tirzepatide. [4] [7] [12] [13]
Connecticut notes on specific peptides
- Semaglutide: Available branded by prescription from a Connecticut-licensed provider, including after an asynchronous store and forward evaluation under section 19a-906 that meets the in-person standard of care, with access to or knowledge of the patient's medical history and health record. Compounded semaglutide is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025, and out-of-state compounded vials require an approved sterile compounding addendum. [2] [5] [11]
How to check a compounding pharmacy in Connecticut
- Search the Connecticut Commission of Pharmacy (Department of Consumer Protection, Drug Control Division) license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Connecticut requires before it ships to you. [1] [3] [4] [5] [6] [8]
- Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
- Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
- Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Connecticut. [4] [7] [12] [13]
Common questions in Connecticut
What does an out-of-state pharmacy need to send me injectable compounded peptides in Connecticut?
A nonresident pharmacy registration under section 20-627 plus an approved sterile compounding addendum under section 20-633b, which requires proof of a passed home-state inspection and written approval from the Department of Consumer Protection and the Commission of Pharmacy before any sterile product is shipped. [4] [5]
Can a Connecticut pharmacy compound BPC-157?
Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). State law still applies: Connecticut has no separate state bulks list, so peptide eligibility follows the federal 503A framework. [9] [10] [14] [15]
Sources
- [1]Connecticut Commission of Pharmacy, Department of Consumer Protection
- [2]Connecticut General Statutes, 2026 Supplement, chapter 368ll, section 19a-906, Telehealth services (as amended by P.A. 25-97 and P.A. 25-168), accessed 2026-09-30
- [3]Connecticut General Statutes chapter 400j, Pharmacy
- [4]Connecticut General Statutes section 20-627, Nonresident pharmacy registration
- [5]Connecticut General Statutes section 20-633b, Sterile compounding pharmacies
- [6]Regulations of Connecticut State Agencies sections 20-576-64 to 20-576-68, Sterile compounding pharmacies (standards in section 20-576-66, adopted effective July 12, 2011), accessed 2026-09-22
- [7]Connecticut General Statutes chapter 418 (Connecticut Food, Drug and Cosmetic Act), section 21a-110, New drugs, accessed 2026-09-22
- [8]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
- [9]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
- [10]FDA: Pharmacy Compounding Advisory CommitteeFDA